Current technology using antibodies, siRNA, and small molecule compounds enables only 400 out of 3,000 disease-inducing genes to be targeted by drugs. The fact that 85% of targets such as scaffold proteins, regulators, aggregates, transcription factors are still undruggable is a limitation yet to be overcome, and the side effects and resistance of pre-existing drugs are demanding the introduction of a next generation drug.
Conventional technology has its weaknesses in certain drug profiles, such as intracellular target, tissue permeability, and administration route. Degraducer® technology, however, is a powerful platform technology that satisfies all profiles.
|Division||Antibody||siRNA||Small molecule compound||Degraducer®|
|Whole body distribution||O||O||X||O|
|Target protein elimination||X||O||X||O|
|High efficacy and selectivity||O||O||Poor||O|